Trials / Completed
CompletedNCT01149824
Placebo Controlled Study of Sublingual Salvinorin A
A Double Blind Placebo Controlled Ascending Dose Pharmacodynamic and Tolerability Study of 100 to 4000 µg of Sublingual Salvinorin A
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 8 (actual)
- Sponsor
- California Pacific Medical Center Research Institute · Academic / Other
- Sex
- All
- Age
- 21 Years – 45 Years
- Healthy volunteers
- Not accepted
Summary
In this study, our aim is to determine an active but tolerable sublingual dose (range 100 to 4000 µg) of Salvinorin A (SA) in experienced subjects. This study is an ascending-dose, placebo-controlled, single-site design in 8 Salvia-experienced subjects. Subjects will receive SA doses from 0-4000 µg. Doses will be separated by at least one day. The first two doses (0 and 100µg) will be double-blinded while the last four (250, 500, 1000, 2000 and 4000µg) will be single-blind.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Salvinorin A | |
| DRUG | Placebo |
Timeline
- Start date
- 2009-06-01
- Primary completion
- 2009-12-01
- Completion
- 2010-10-01
- First posted
- 2010-06-24
- Last updated
- 2013-05-31
Source: ClinicalTrials.gov record NCT01149824. Inclusion in this directory is not an endorsement.